Founded in 2019 and led by CEO Sandy Mou, Corxel Pharmaceuticals (formerly JiXing Pharmaceuticals) focuses on discovering, developing, and commercializing therapies for cardiometabolic conditions. Its lead candidate, CX11, is in an ongoing U.S. Phase 2 trial for obesity and overweight patients and is scheduled for a global Phase 2 study targeting Type 2 Diabetes Mellitus, with Phase 3 preparations already underway. Beyond CX11, the company’s pipeline spans assets for hypertension, acute ischemic stroke, and ophthalmologic indications such as dry eye and presbyopia. Proceeds from its recent financing will also support advancement of these additional programs and expand global operational capabilities needed for multiregional clinical trials. The company operates from offices in Berkeley Heights, New Jersey, and China. As a clinical-stage firm, Corxel has not disclosed commercial revenues, but the latest capital infusion provides significant runway to progress multiple candidates through late-stage development.

Total raised

$449M

Funding rounds

3

Latest round

Series D

Latest activity

Jan 2026